Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 6/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 1.00 |
| ▸ | APP | P05067 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 1/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 1/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorogenic Acid SCHEMBL19466 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL13015035 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL22111591 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL13250699 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL24239743 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL21191546 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL24879283 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL21433650 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL22422499 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL21142437 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303059-B2 | Chemoselective enrichment for compound isolation | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160082025-A1 | USING DNA METHYLTRANSFERASE INHIBITORS TO TREAT CALCIFIC AORTA VALVE DISEASE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2016-03-24 | — | — | US | disclosed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140107328-A1 | CHEMOSELECTIVE ENRICHMENT FOR COMPOUND ISOLATION | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2014-04-17 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | AKR1B1 1357/4885PTPN1 4039/4885APP 145/4885 |
| US-20160082025-A1 | USING DNA METHYLTRANSFERASE INHIBITORS TO TREAT CALCIFIC AORTA VALVE DISEASE | DNMT1, DNMT3A, DNMT3B | AKR1B1 2459/4885PTPN1 4527/4885APP 3342/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | AKR1B1 1787/4885PTPN1 4641/4885APP 124/4885 |
| US-20140107328-A1 | CHEMOSELECTIVE ENRICHMENT FOR COMPOUND ISOLATION | PAH, HAAO, APEH | AKR1B1 609/4885PTPN1 4087/4885APP 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.